We have analyzed the distribution of tumor necrosis factor (TNF) a and-b microsatellite alleles in HLA-DQ and-DR typed Swedish patients with multiple sclerosis (MS) (n=l22) and ethnically matched control subjects (n=l78). We found significant differences in the frequencies of TNFa and TNFb alleles between patients and controls. TNFal I was significantly associated with MS. This was also the case for the combination of TNFal I with TNFb4. However, TNFal I (alone or in combination with TNFb4) did not show any disease association independent of DQA 1*01021 DQBI*0602/DR2, whereas the previously reported strong association with HLA-DQAI*0102/DQBI*0602/DR2 in Scandinavian populations was confirmed. Therefore the association of TNFal I (and TNFb4) is most likely secondary to the increase of DQAI*0102/DQBl*0602/DR2 in MS patients. The proportion of TNFa6 positive individuals was lower among DR2-negative MS patients than among DR2-negative controls (p=0.08). Since the presence of the TNFab allele correlates with low TNFα production in response to lipopolysaccharide, it could be speculated that DR2-negative MS patients have an increased risk of being high TNFα producers in response to exogenous stimuli.
1 Martin R, McFarland HF, McFarlin DE. (1992) Immunological aspects of demyelinating diseases. Ann Rev Immunol10: 153–187.
2.
2 Raine CS. (1991) Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neubiol17: 265–274.
3.
3 Selmaj K, Raine CS, Cannella B, Brosnan CF. (1991). Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest87: 949–954.
4.
4 Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. (1993). Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lympho-trophic virus type I-associated myelopathy. Ann Neurol33: 646–649.
5.
5 Allen M et al. (1994) Association to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum Immunol39: 41–48.
6.
6 Tienari P et al. (1994) Two-locus linkage analysis in multiple scleroses (MS). Genomics19: 320–325.
7.
7 Nedwin GE et al. (1995) Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res13: 6361–6373.
8.
8 Nedospasov SA et al. (1996) Tandem arrangement of genes coding for tumor necrosis factor (TNFα) and lymphotoxin (TNFβ) in the human genome. Cold Spring Harbor Symp Quant Biol51: 611–624.
9.
9 Hof man FM, Hinton DR, Johnson K, Merrill JE. (1989). Tumor necrosis factor identified in multiple sclerosis. J Exp Med170: 607–612.
10.
10 Beck J et al. (1988). Increased production of interferon γ and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?Acta Neurol Scand78: 318–323.
11.
11 Merrill JE, Strom SR, Ellison GW, Meyers LW. (1989). In vitro study of mediators of inflammation in multiple sclerosis. J Clin Immunol9: 84–96.
12.
12 Pociot F et al. (1991). A tumour necrosis factor beta gene polymorphism in relation to monokines secretion and insulin-dependent diabetes mellitus. Scand J Immunol33: 37–49.
13.
13 Pociot F et al. (1993). Association of tumor necrosis factor (TNF) and class II MHC alleles with the secretion of TNFα and TNFβ by human mononuclear cells: A possible link to insulin-dependent diabetes mellitus. Eur J Immunol23: 224–231.
14.
14 Pociot F, Wilson AG, Nerup J, Duff GW. (1993). No independent association between a TNFα promoter region polymorphism and insulin-dependent diabetes mellitus (IDDM). Eur J Immunol23: 3050–3053.
15.
15 Pociot F et al. (1994). Analysis of a new TNFA promoter polymorphism on the IDDM-associated HLA-B18,-DR3 haplotype.Eur J Endocrinol130: (suppl 1): 31.
16.
16 Roth M-P et al. (1994). Tumor necrosis factor polymorphisms in multiple sclerosis: no additional association independent of HLA. J Neuroimmunol51: 93–99.
17.
17 Crouau-Roy B et al. (1993). TNF microsatellites in four European populations. Hum Immunol38: 213–216.
18.
18 Poser CM et al. (1983). New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol13: 227–231.
19.
19 Jongeneel CV et al. (1991). Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes.Proc Natl Acad Sci (USA), 88: 9717–9721.
20.
20 Svejgaard A, Ryder LP. (1994). HLA and disease associations: Detecting the strongest association. Tissue Antigens43: 18–27.
21.
21 Powell MB, Steinman L. (1992). The role of lymphotoxin and TNF in demyelinating diseases of the CNS. In: Beutler B (ed). Tumor necrosis factor. The molecule and their emerging role in medicine.Raven Press, New York: 355–369.
22.
22 Merrill JE, Ellison GW, Myers LW. (1984). Cytotoxic activity of peripheral blood and cerebrospinal fluid lymphocytes from patients with multiple sclerosis and other neurological diseases: analysis at the single cell level of the relationship of cytotoxic effects and interferon-producing cells. Clin Immunol Immuno-pathol31: 390–402.
23.
23 Franciotta DM et al. (1989). Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol26: 787–789.
24.
24 Gallo P, Piccinno MG, Krzalic L, Tavolato B. (1989). Tumor necrosis factor alpha (TNF-α) and neurological diseases. Failure in detecting TNFα in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumor. J Neuroimmunol23: 41–44.
25.
25 Hauser SL et al. (1990). Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology40: 1735–1739.
26.
26 Maimone D, Gregory S, Arnason BGW, Reder AT (1991). Cytokine levels in cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol32: 67–74.
27.
27 Sharief MK, Hentges R. (1991). Association between tumor necrosis factorα and disease progression in patients with multiple sclerosis. N Engl J Med325: 467–472.
28.
28 Peter JB, Boctor FN, Tourtellotte WW. (1991). Serum and CSF levels of IL-2, sIL-2, TNFα, and IL-1β in chronic progressive multiple sclerosis. Expected lack of clinical utility.Neurology, 41: 121–123.
29.
29 Sharief MK et al. (1994). Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNFα and blood-brain barrier damage. J Neuroimmunol43: 15–22.
30.
30 Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. (1994). Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1αssociated myelopathy. J Neuroimmunol52: 33–40.
31.
31 Chofflon M et al. (1992). Tumor necrosis factor α production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Network3: 523–531.
32.
32 Rudick RA, Ransohoff RM. (1992). Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch Neurol49: 265–270.
33.
33 Mølvig J et al. (1988). Endotoxin-stimulated human monocyte secretion of inter-leukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable inter-individual differences. Scand J Immunol27: 705–716.
34.
34 Robbins DS et al. (1987). Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol139: 2593–2597.
35.
35 Selmaj K, Raine CS. (1988). Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol23: 339–346.
36.
36 Ruddle NH et al. (1990). An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med172: 1193–1200.
37.
37 Udalova IA et al. (1993). Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics16: 180–186.
38.
38 Powell MB et al. (1990). Lymphotoxin and tumor necrosis factorα production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol2: 539–544.
